ATE540683T1 - Therapeutische verwendung von cpg- oligodeoxynukleotid bei hautkrankheiten - Google Patents

Therapeutische verwendung von cpg- oligodeoxynukleotid bei hautkrankheiten

Info

Publication number
ATE540683T1
ATE540683T1 AT05820420T AT05820420T ATE540683T1 AT E540683 T1 ATE540683 T1 AT E540683T1 AT 05820420 T AT05820420 T AT 05820420T AT 05820420 T AT05820420 T AT 05820420T AT E540683 T1 ATE540683 T1 AT E540683T1
Authority
AT
Austria
Prior art keywords
skin diseases
therapeutic use
cpg
cpg oligodeoxynucleotide
odns
Prior art date
Application number
AT05820420T
Other languages
English (en)
Inventor
Doo-Sik Kim
Hyung-Joo Kwon
Yang-Soon Kim
Tae-Yoon Kim
Dong-Heon Shin
Original Assignee
Bio Clue & Solution Co Ltd
Tae-Yoon Kim
Dong-Heon Shin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Clue & Solution Co Ltd, Tae-Yoon Kim, Dong-Heon Shin filed Critical Bio Clue & Solution Co Ltd
Application granted granted Critical
Publication of ATE540683T1 publication Critical patent/ATE540683T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05820420T 2004-11-05 2005-11-04 Therapeutische verwendung von cpg- oligodeoxynukleotid bei hautkrankheiten ATE540683T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040090000A KR100721928B1 (ko) 2004-11-05 2004-11-05 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
PCT/KR2005/003717 WO2006049454A1 (en) 2004-11-05 2005-11-04 Therapeutic use of cpg oligodeoxynucleotide for skin disease

Publications (1)

Publication Number Publication Date
ATE540683T1 true ATE540683T1 (de) 2012-01-15

Family

ID=36319422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05820420T ATE540683T1 (de) 2004-11-05 2005-11-04 Therapeutische verwendung von cpg- oligodeoxynukleotid bei hautkrankheiten

Country Status (7)

Country Link
US (1) US7935678B2 (de)
EP (1) EP1807094B1 (de)
JP (1) JP5101282B2 (de)
KR (1) KR100721928B1 (de)
CN (1) CN1938035B (de)
AT (1) ATE540683T1 (de)
WO (1) WO2006049454A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100906970B1 (ko) * 2006-06-03 2009-07-10 주식회사 바이오씨에스 피부 면역질환에 대한 ＣｐＧ 올리고데옥시뉴클레오티드의치료학적 용도
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100322909A1 (en) * 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy
EP2451461A4 (de) 2009-07-06 2013-05-29 Ontorii Inc Neuartige nukleinsäure-prodrugs und verwendungsverfahren dafür
CN101914541B (zh) * 2010-08-09 2013-03-13 华中科技大学同济医学院附属同济医院 抑制mbd2表达的抑制剂及其应用
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
JP2014012650A (ja) * 2012-07-05 2014-01-23 Nihon Univ 上皮バリア機能の増強方法及び増強剤
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
EP3095459A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
EP3095461A4 (de) * 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
WO2015108046A1 (ja) * 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3094728B1 (de) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chirales design
CN104195235B (zh) * 2014-04-28 2017-06-16 云南沃森生物技术股份有限公司 检测CpG ODN序列纯度的方法及应用
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
JP6762030B2 (ja) * 2014-11-20 2020-09-30 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CA3023451A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
EP0092574B1 (de) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonukleotides heilmittel und dessen herstellungsverfahren
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US6077833A (en) 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
HU228264B1 (en) * 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
KR100681470B1 (ko) 2003-03-03 2007-02-12 연세대학교 산학협력단 면역반응 증진용 올리고뉴크레오타이드
CN101675993A (zh) * 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物

Also Published As

Publication number Publication date
CN1938035A (zh) 2007-03-28
US20090062224A1 (en) 2009-03-05
JP5101282B2 (ja) 2012-12-19
JP2008502713A (ja) 2008-01-31
CN1938035B (zh) 2011-07-20
EP1807094B1 (de) 2012-01-11
KR20060040417A (ko) 2006-05-10
WO2006049454A1 (en) 2006-05-11
EP1807094A1 (de) 2007-07-18
EP1807094A4 (de) 2008-07-23
US7935678B2 (en) 2011-05-03
KR100721928B1 (ko) 2007-05-28

Similar Documents

Publication Publication Date Title
EP1807094A4 (de) Therapeutische verwendung von cpg-oligodeoxynukleotid bei hautkrankheiten
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
CY1108870T1 (el) Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους
WO2001051083A3 (en) Innate immunity-stimulating compositions of cpg and saponin and methods thereof
EP1664342A4 (de) Selektive modulation der expression des tlr-gens
MX2009012482A (es) Oligonucleotidos de clase a con potencia inmunoestimuladora.
DE60131430D1 (de) Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
DE602004028956D1 (de) Verbesserungen bei bzw. betreffend polynukleotidarrays
CY2016020I2 (el) Στελεχη ιου του ερπη για γονιδιακη θepαπεια
AU2001290706A1 (en) Antisense modulation of clusterin expression
MXPA03002453A (es) Uso de imidazoquinolinaminas como mejoradores de vacunacion de acido desoxirribonucleico.
AU2002353783A8 (en) Suppressors of cpg oligonucleotides and methods of use
DE60130723D1 (de) Implantierbarer Herzschrittmacher zur Optimierung der Reizungseffektivität
EP1687449A4 (de) Antisense-modulation der expression von kinesin-like 1
EP1290005A4 (de) Vegf-modulierte gene und verfahren, die diese verwenden
ES2674129T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
AU2003255969A8 (en) Use of cpg nucleic acids in prion-disease
EP1417216A4 (de) Antisense-modulation der bcl2 assoziierten x-protein-expression
NO20043953L (no) TRPM-2-antisenseterapi som anvender et antinukleotid med 2`-O-(2-metoksyl)etyl-modifiseringer
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
EP1635765A4 (de) Strukturbasiertes und kombinatorisch ausgewähltes oligonucleosid-phosphorothioat und phosphorodithioat aptamer targeting ap-1 transkriptionsfaktoren
AU2003273686A1 (en) Partially double-stranded hairpin oligonucleotides immobilizable via the looped end and comprising a restriction site
EP1248795A4 (de) Antisens-modulierung der expression des makrophagenmigrationshemmenden faktors
EP1506216A4 (de) Antisense-modulierung der kinesin-like-1-expression
WO2001098454A8 (en) Human dna sequences